Skip to main content
Year archive

Innovent Biologics, Inc. — 2022 filings

All 58 regulatory filings released by Innovent Biologics, Inc. (1801) in 2022, sourced directly from the official regulator.

58 Filings
2022 Period
2022 filings (58)
Filing Released Lang
TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE
Remuneration Information
2022-12-30 English
VOLUNTARY ANNOUNCEMENT - INNOVENT AND LG CHEM ANNOUNCE STRATEGIC COLLABORATION FOR TIGULIXOSTAT, A NOVEL NON-PURINE XANTHINE OXIDASE INHIBITOR FOR THE TREATMENT OF GOUT DISEASE
Capital/Financing Update
2022-12-15 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Share Issue/Capital Change
2022-12-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
Regulatory Filings
2022-12-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
Regulatory Filings
2022-11-04 English
RESTATEMENT OF THE FINANCIAL STATEMENTS OF THE COMPANY FOR THE YEAR ENDED 31 DECEMBER 2021
Audit Report / Information FY 2021
2022-11-01 English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE THIRD QUARTER OF 2022
Regulatory Filings
2022-11-01 English
SUPPLEMENTAL DETAILED DISCLOSURE OF THE USE OF PROCEEDS OF THE PAST FUND RAISED
Capital/Financing Update
2022-10-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
Regulatory Filings
2022-10-10 English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES THE NEW DRUG APPLICATION FOR SELPERCATINIB FOR THE TREATMENT OF PATIENTS WITH RET-DRIVEN LUNG AND THYROID CANCERS
Regulatory Filings
2022-10-10 English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CYRAMZA (RAMUCIRUMAB) FOR THE TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINO
Regulatory Filings
2022-10-10 English
2022 INTERIM REPORT
Interim / Quarterly Report H1 2022
2022-09-28 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
Regulatory Filings
2022-09-07 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Transaction in Own Shares
2022-08-29 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2022
Interim / Quarterly Report H1 2022
2022-08-25 English
COMPLETION OF ISSUANCE OF SHARES TO SANOFI UNDER GENERAL MANDATE
Capital/Financing Update
2022-08-18 English
DATE OF BOARD MEETING
Report Publication Announcement
2022-08-09 English
(1) STRATEGIC MULTI-PROGRAM COLLABORATION AND LICENSE AGREEMENT ENTERED INTO WITH SANOFI&#x3b; AND (2) ISSUE OF SUBSCRIPTION SHARES TO SANOFI UNDER GENERAL MANDATE PURSUANT TO SHARE ISSUANCE AGREEMENT
Capital/Financing Update
2022-08-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
Regulatory Filings
2022-08-04 English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE SECOND QUARTER OF 2022
Regulatory Filings
2022-08-04 English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED AND GRANTED PRIORITY REVIEW DESIGNATION TO A NEW DRUG APPLICATION FOR OLVEREMBATINIB FOR THE TREATMENT OF DRUG-RESISTANT
Regulatory Filings
2022-07-19 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Share Issue/Capital Change
2022-07-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022
Regulatory Filings
2022-07-07 English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES THE SUPPLEMENTAL NEW DRUG APPLICATION FOR TYVYT (SINTILIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TRE
Regulatory Filings
2022-06-24 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 22, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-23 English
CLARIFICATION ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES THE SUPPLEMENTAL NEW DRUG APPLICATION FOR TYVYT (SINTILIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE
Regulatory Filings
2022-06-20 English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR TYVYT(SINTILIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREA
Regulatory Filings
2022-06-20 English
VOLUNTARY ANNOUNCEMENT - THE APPROVAL OF BEVAGEN (BEVACIZUMAB BIOSIMILAR) BY THE INDONEDIAN FOOD AND DRUGS AUTHORITY
Regulatory Filings
2022-06-14 English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR TAFOLECIMAB INJECTION (ANTI-PCSK-9 ANTIBODY)
Regulatory Filings
2022-06-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2022
Share Issue/Capital Change
2022-06-07 English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR EQUECABTAGENE AUTOLEUCEL FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELO
Regulatory Filings
2022-06-02 English
GRANT OF SHARE OPTIONS AND NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO AN INDEPENDENT NON-EXECUTIVE DIRECTOR
Director's Dealing
2022-06-01 English
2021 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information
2022-06-01 English
Form of Proxy for use at the Annual General Meeting to be held on Wednesday, June 22, 2022
AGM Information
2022-06-01 English
PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE NEW SHARES, PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS AND ELECTION OF A DIRECTOR, PROPOSED GRANTS OF RESTRICTED SHARES TO DIR
AGM Information
2022-06-01 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2022-06-01 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information
2022-06-01 English
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, CHANGE IN THE COMPOSITION OF BOARD COMMITTEES
Board/Management Information
2022-06-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
Regulatory Filings
2022-05-10 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE
Capital/Financing Update
2022-05-06 English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE PRODUCT REVENUE IN THE FIRST QUARTER OF 2022
Capital/Financing Update
2022-04-28 English
2021 ANNUAL REPORT
Annual Report FY 2021
2022-04-28 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
Share Issue/Capital Change
2022-04-08 English
INSIDE INFORMATION - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES PEMAZYRE (PEMIGATINIB) FOR THE TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION
Regulatory Filings
2022-04-06 English
GRANT OF SHARE OPTIONS AND NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO DIRECTORS AND GRANT OF RESTRICTED SHARES
Capital/Financing Update
2022-03-31 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021
Annual Report FY 2021
2022-03-29 English
VOLUNTARY ANNOUNCEMENT - INNOVENT AND LILLY EXPAND STRATEGIC PARTNERSHIP IN ONCOLOGY
Capital/Financing Update
2022-03-28 English
INSIDE INFORMATION - FDA ISSUES COMPLETE RESPONSE LETTER FOR SINTILIMAB IN COMBINATION WITH PEMETREXED AND PLATINUM CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF PEOPLE WITH NONSQUAMOUS NON-SMALL
Regulatory Filings
2022-03-24 English
DATE OF BOARD MEETING
Report Publication Announcement
2022-03-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022
Regulatory Filings
2022-03-04 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information
2022-02-25 English
RESIGNATION OF NON-EXECUTIVE DIRECTOR&#x3b; CHANGE IN COMPOSITION OF AUDIT COMMITTEE
Board/Management Information
2022-02-25 English
VOLUNTARY ANNOUNCEMENT - FDA ADVISORY COMMITTEE VOTES ON THE BIOLOGICS LICENSE APPLICATION OF SINTILIMAB FOR FIRST-LINE TREATMENT OF NONSQUAMOUS NON-SMALL CELL LUNG CANCER
Regulatory Filings
2022-02-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022
Regulatory Filings
2022-02-09 English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON SALES OF TYVYT (SINTILIMAB INJECTION) IN THE FOURTH QUARTER OF 2021
Regulatory Filings
2022-02-04 English
INSIDE INFORMATION ANNOUNCEMENT-THE HONG KONG DEPARTMENT OF HEALTH HAS APPROVED PEMAZYRE (PEMIGATINIB) FOR THE TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBL
Regulatory Filings
2022-01-24 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
Regulatory Filings
2022-01-06 English
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE AND TRADING VOLUME MOVEMENT
Regulatory Filings
2022-01-05 English